Sixth edition of Australasian Leukaemia and Lymphoma Group (ALLG) quarterly newsletter – ALLG News.
Our latest community news, ALLG News Edition 6, is here! You can read about progress in blood cancer treatment, the future of clinical trials, the role trial coordinators play in improving cancer care, and much more.
At our most recent Scientific Meeting in October, we celebrated our Group’s 50th anniversary and honoured some of ALLG’s outstanding members for their important contributions to blood cancer treatments. You can read about it in this newsletter, as well as the latest ALLG lymphoma trials and the Patient Forum we co-hosted with Lymphoma Australia.
This ALLG News also features insights from our Scientific Advisory Committee Chair, Professor Judith Trotman, on the future of clinical trials and how they will impact positively on patient care.
As the only not-for-profit collaborative clinical trials group in Australia and New Zealand for blood cancers, the ALLG conducts independent doctor-led clinical trials in Australasia and, crucially, participates in many international trials. This provides access to new treatments for patients locally that would not otherwise be available.
We hope you enjoy the latest edition of ALLG News!
You can read ALLG News Edition 6 here and find past editions of ALLG News here.
You can subscribe to future editions of ALLG News here.
About the ALLG:
As the only non-profit collaborative clinical trials groups in Australia and New Zealand for blood cancers, the ALLG has the capability to run independent doctor-led clinical trials in Australasia and, crucially, to participate in teletrials and international trials; allowing us access to new treatments, with the potential to make a significant impact on patient outcome.
You can also follow us on Twitter, Linkedin and Facebook.
Did you know that the ALLG is registered charity? Find out ways you can support the mission for better treatments, better lives for patients with blood cancer. Learn more here and read about you can help accelerate the ALLG’s research impact.